Skip to main content
Equibles

Stéphane Bancel

CEO

Moderna, Inc. (MRNA)

Board Member

Moderna, Inc. (MRNA)

Equibles does not estimate personal net worth.

Get an email with a short summary when Moderna, Inc. publishes a filing, an earnings call transcript or a press release.

Get MRNA alerts

About Stéphane Bancel

Stéphane Bancel is recorded as Board Member at Moderna, Inc. (MRNA) since January 1, 2011 and CEO at Moderna, Inc. (MRNA). The newest filing on record that lists Stéphane Bancel as Board Member at Moderna, Inc. (MRNA) is dated March 21, 2024. The newest filing on record that lists Stéphane Bancel as CEO at Moderna, Inc. (MRNA) is dated March 16, 2020. The proxy statement of Moderna, Inc. reports total compensation of $19,932,217 for Stéphane Bancel in fiscal 2025, including a base salary of $1,677,739. Disclosed compensation is on record for 9 fiscal years. Stéphane Bancel has spoken on 25 earnings calls across 1 company, most recently for Moderna, Inc. on July 31, 2026. Moderna, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Moderna, Inc. includes Noubar Afeyan (Chairman and Board Member), David W. Meline (CFO), James Mock (CFO) and 7 others.

Stéphane Bancel on recent calls

“After my review of the second quarter, Jamie will present our financial results and outlook, followed by Stephen will present business updates. Then David will review our clinical progress in oncology and rare diseases.”
CEO, Moderna Q2 Earnings call ·
“I will start with a review of our first quarter, Jamie with a cover of financial results and outlook, followed by Stephen on commercial and clinical progress. I will close by discussing our value drivers before we take your questions.”
CEO, Moderna, Inc. Q1 FY2026 Earnings Call ·
“I will start with a quick review of 2025. Jamie will present our financial results and 26 outlook. Steven will review our commercial outlook and clinical programs.”
CEO, Moderna, Inc. Q4 FY2025 Earnings Call ·
“Jamey will present our financial results and outlook. Stephen will review our clinical programs, and then I will come back and share our key priorities and catalysts before we take your questions.”
CEO, Moderna, Inc. Q2 FY2025 Earnings Call ·
“I will start with a review of our business in Q1. Jamey will present our financial results and our outlook. Stephen will review our clinical programs and I will come back to some key priorities and catalysts before we take your questions.”
CEO, Moderna, Inc. Q1 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Moderna, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Moderna, Inc. (MRNA) $1,677,739 $19,932,217
2024 Moderna, Inc. (MRNA) $1,625,885 $19,876,180
2023 Moderna, Inc. (MRNA) $1,563,462 $17,068,514
2022 Moderna, Inc. (MRNA) $1,423,077 $19,363,648
2021 Moderna, Inc. (MRNA) $990,385 $18,155,739
2020 Moderna, Inc. (MRNA) $945,673 $12,885,275
2019 Moderna, Inc. (MRNA) $921,217 $8,948,207
2018 Moderna, Inc. (MRNA) $863,077 $58,608,484
2017 Moderna, Inc. (MRNA) $650,769 $6,809,189

Recent activity

Show 13 earlier activities